Table 4. Percentage of study participants taking antihypertensive medication with BP above treatment goals recommended by the 2017 ACC/AHA and the 2018 KSH guidelines.

Variables		BP above goal according to		2017 ACC/AHA but not 2018 KSH
		2017 ACC/AHA guideline	2018 KSH guideline
Overall		61.7 (60.5–62.9)	45.6 (44.4–46.8)	16.1 (15.2–16.8)
Age group (year)
	20–29	63.1 (26.0–100.0)	36.2 (5.7–66.7)	26.9 (26.5–27.4)
	30–39	84.5 (78.4–90.6)	46.1 (37.1–55.2)	38.4 (38.1–38.8)
	40–49	74.9 (71.5–78.4)	42.1 (38.2–46.0)	32.8 (32.2–33.3)
	50–59	69.1 (66.8–71.4)	42.4 (40.0–44.9)	26.7 (26.1–27.1)
	60–69	56.6 (54.7–58.5)	45.1 (43.2–47.1)	11.5 (11.2–12.0)
	70–79	54.7 (52.7–56.8)	50.3 (48.3–52.3)	4.4 (3.9–5.0)
	80+	53.8 (49.8–57.8)	48.6 (44.5–52.6)	5.2 (5.0–5.5)
Sex
	Male	63.5 (61.8–65.2)	45.6 (43.8–47.3)	17.9 (17.5–18.6)
	Female	60.1 (58.6–61.6)	45.6 (44.1–47.1)	14.5 (14.2–14.8)
Number of ASCVD risk factors*
	0	58.6 (53.8–63.5)	35.2 (30.3–40.1)	23.4 (23.0–23.8)
	1–2	61.7 (60.0–63.5)	38.3 (36.5–40.0)	23.4 (23.1–23.8)
	≥3	62.3 (60.7–63.9)	49.0 (47.3–50.6)	13.3 (12.7–13.8)
Predicted 10-year ASCVD risk†
	<5%	65.2 (62.4–67.9)	28.7 (26.0–31.4)	36.5 (36.3–36.8)
	≥5% and <10%	65.2 (62.8–67.5)	40.5 (38.0–43.0)	24.7 (24.3–25.0)
	≥10% and <20%	57.3 (55.3–59.2)	50.5 (48.5–52.4)	6.8 (6.1–7.5)
	≥20%	61.1 (59.2–63.0)	57.2 (55.2–59.1)	3.9 (3.7–4.3)
History of CVD
	Yes	57.7 (55.9–59.5)	36.8 (35.1–38.5)	20.9 (20.0–21.6)
	No	60.0 (57.1–63.0)	58.5 (55.5–61.5)	1.5 (0.9–1.9)

Values are presented as weighted % (95% confidence interval).

ACC/AHA = American College of Cardiology/American Heart Association; ASCVD = atherosclerotic cardiovascular disease; BP = blood pressure; CVD = cardiovascular diseases; KSH = Korean Society of Hypertension.

^*Number of ASCVD risk factors are based on the 2018 KSH guideline. ^†Predicted 10-year ASCVD risk is derived from the Korean Risk Prediction Model.